We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RNAZ TransCode Therapeutics Inc

0.018 (2.69%)
Last Updated: 12:21:30
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
TransCode Therapeutics Inc RNAZ NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.018 2.69% 0.688 12:21:30
Open Price Low Price High Price Close Price Previous Close
0.67 0.6502 0.689 0.67
more quote information »

Recent News

Date Time Source Heading
2/20/202407:00GLOBETransCode Therapeutics Reports Publication of United States..
2/15/202415:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
2/13/202419:12EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
1/31/202415:33EDGAR2Form 8-K - Current report
1/31/202415:05GLOBENasdaq Determines TransCode Therapeutics Compliance with..
1/29/202407:30GLOBETransCode Therapeutics and Debiopharm Announce Collaboration..
1/22/202415:45EDGAR2Form 8-K - Current report
1/22/202415:45GLOBETransCode Therapeutics Announces Closing of $7.25 Million..
1/19/202420:57EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
1/18/202423:15EDGAR2Form EFFECT - Notice of Effectiveness
1/18/202412:27GLOBETransCode Therapeutics Announces Pricing of $7.25 Million..
1/18/202409:39EDGAR2Form S-1/A - General form for registration of securities..
1/17/202406:06EDGAR2Form S-1/A - General form for registration of securities..
1/16/202415:01EDGAR2Form 8-K - Current report
1/12/202415:05GLOBETransCode Therapeutics Reports Further Restructuring to..
1/11/202407:22EDGAR2Form S-1 - General form for registration of securities under..
1/11/202407:00GLOBETransCode Therapeutics Announces 1-for-40 Reverse Stock..
1/08/202415:01EDGAR2Form 8-K - Current report
1/04/202411:41EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
1/04/202407:05GLOBETransCode Therapeutics Publishes Open Letter Outlining..
12/18/202315:28EDGAR2Form DEF 14A - Other definitive proxy statements
12/12/202307:30GLOBETransCode Therapeutics Reports Positive Pre-Clinical Results..
12/08/202315:57EDGAR2Form PRE 14A - Other preliminary proxy statements
12/08/202315:56EDGAR2Form 8-K - Current report
12/07/202315:30EDGAR2Form SC 13G - Statement of acquisition of beneficial..
12/05/202308:00GLOBETransCode Therapeutics To Present Phase 0 Data at 2023 San..
12/04/202316:07EDGAR2Form 8-K - Current report
12/04/202315:10GLOBETransCode Therapeutics Announces Closing of $1.2 Million..
12/01/202316:23EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
11/30/202313:53GLOBETransCode Therapeutics Announces $1.2 Million Registered..
11/14/202315:40EDGAR2Form 8-K - Current report
11/14/202315:30GLOBETransCode Therapeutics Reports Third Quarter 2023 Results;..
11/09/202315:13EDGAR2Form 8-K - Current report
10/31/202321:20APSBiotech Shares Bid Up Following Public Offering Cancellation
10/30/202315:33GLOBETransCode Therapeutics Withdraws Public Offering
10/27/202315:06EDGAR2Form 8-K - Current report
10/27/202307:00GLOBENasdaq Panel Grants TransCode Therapeutics Extension for..
10/26/202315:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/26/202315:19GLOBETransCode Therapeutics Announces Public Offering of Common..
10/26/202307:00GLOBETransCode Therapeutics Announces Prolonged Survival in..
10/24/202307:05EDGAR2Form 8-K - Current report
10/24/202307:00GLOBETransCode Therapeutics Announces Preliminary Clinical..
10/16/202307:00GLOBETransCode Therapeutics Reports Successful Treatment of..
10/10/202315:00EDGAR2Form SC 13D/A - General statement of acquisition of..
10/02/202315:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/02/202315:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
9/28/202315:07EDGAR2Form 8-K - Current report
9/28/202315:02GLOBETransCode Therapeutics Announces Closing of $8.5 Million..
9/27/202316:26EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
9/25/202319:01GLOBETransCode Therapeutics Announces Pricing of $8 Million..

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |